The zero-observation outcome reflects the company's robust quality management systems and commitment to excellence in its operations.
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
The company reported lifetime high EBIDTA of Rs. 250 crores
This latest audit re-emphasizes Hikal's commitment towards maintaining the best in class quality, compliance and regulatory standards across our manufacturing sites
This acquisition will boost Neogen's portfolio by offering organolithium derivatives to existing pharma industry
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
Subscribe To Our Newsletter & Stay Updated
